Biomarker Type: Proteomic
-
Predicting prognosis in COVID-19 patients using machine learning and readily available clinical data
-
Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based Test
-
Potential role of serum proteome in predicting immune-related adverse events from immunotherapy in non-small cell lung cancer
-
Longitudinal blood-based proteomic testing in advanced non-small cell lung cancer
-
Old Habits Die Hard: Managing Lung Nodules With Size Alone Is Not Sufficient
-
Utilizing Serum Proteome to Understand Response and Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
-
The Impact of Blood-Based Host Immune Profiling to Identify Aggressive Early-Stage NSCLC
-
Immunotherapy Alone or with Chemotherapy in Advanced NSCLC? Utility of Clinical Factors and Blood-Based Host Immune Profiling
-
Design and Characterization of a Novel Blood Collection and Transportation Device for Proteomic Applications
-
Assessment of Integrated Classifier’s Ability to Distinguish Benign From Malignant Lung Nodules: Extended Analyses and 2 Year Follow-Up Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial